Outcomes of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease.
Ghadeer K DawwasGeoffrey D BarnesPublished in: Current cardiology reports (2022)
Post hoc analyses of randomized clinical trials suggest that DOACs are non-inferior to warfarin for the prevention of stroke or systemic embolism in patients with AF and VHD. Emerging evidence from observational data showed a favorable benefit-risk profile for DOACs compared to warfarin in patients with AF and VHD. DOACs are an attractive option for the treatment of patients with AF and VHD who cannot tolerate or have contraindications to warfarin therapy. Future studies are needed to evaluate their effectiveness, safety, and examine variability in the direction and magnitude of treatment effects in selected VHD subgroups.
Keyphrases
- direct oral anticoagulants
- atrial fibrillation
- venous thromboembolism
- oral anticoagulants
- systematic review
- randomized controlled trial
- metabolic syndrome
- type diabetes
- clinical trial
- stem cells
- machine learning
- pulmonary hypertension
- current status
- combination therapy
- bone marrow
- smoking cessation
- replacement therapy
- aortic valve
- artificial intelligence
- drug induced
- chemotherapy induced